According to filings with the U.S. Securities and Exchange Commission, Outliers dba Thesis is raising $15,391,167.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Daniel Freed played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Outliers dba Thesis
Thesis is the worlds first personalized brain supplement brand. We understand that everyone’s brains are unique and cognitive demands for daily tasks are constantly changing. Our nootropics are a powerful alternative to stimulants, providing similar benefits, minus the jitters, crash, and side effects. Powered by the worlds largest data set on the efficacy of nootropics and advised by neuroscientists from Yale, Penn, and MIT, Thesis quickly and safely delivers increased focus, creativity, energy, and memory in capsule form.

To learn more about Outliers dba Thesis, visit http://takethesis.com/

Contact:
Daniel Freed, Chief Executive Officer
646-647-3599
https://www.linkedin.com/in/freed4life/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.